Myoadenylate deaminase deficiency: inherited and acquired forms.
Myoadenylate deaminase deficiency, the most common of the known enzyme deficits of muscle, appears to occur in two forms. The primary type seems to be inherited as a complete gene block in an autosomal recessive pattern. Although occasionally diagnosed in infancy, when muscle biopsy is performed on a hypotonic but normoreflexic child, the deficiency is usually not symptomatic until adult or middle age, when muscle cramping and exercise intolerance develop. The skeletal muscle isozyme is immunologically, and presumably genetically, unique, and these patients have normal levels of adenylate deaminase in their other cells and tissues. A presumptive diagnosis can usually be made by an ischemic forearm exercise test, which shows a negligible increase in blood ammonia, despite a normal rise in lactate. Despite the absence of more than 99% of normal adenylate deaminase activity, the muscle biopsy shows no anatomic pathology, and other enzymes are at normal levels. These patients do not suffer progressive disease, and should be reassured, and encouraged to maintain physical activity. The heterozygous state is probably asymptomatic, except, perhaps, on extreme exercise, but may be associated with an increased incidence of malignant hyperthermia susceptibility. Since the gene defect is not rare, it is not surprising that some cases of the deficiency will be coincidentally associated with other neuromuscular disease. However, there is also a secondary form of myoadenylate deaminase deficiency, consequent to muscle damage from other disease. In this form, the residual activity is higher (1-10% of normal), may present rare foci of positive stain in the section, and reacts normally with antibody to the muscle isozyme. Other muscle enzymes are also depleted, although not as severely, and the prognosis in such cases is dictated by the primary disease. Since the heterozygous state is common, these patients might have been carriers, whose adenylate deaminase levels have been lowered for the deficient category by the advent of other neuromuscular disease.
D000659:AMP Deaminase / Q000032:analysis / Q000172:deficiency*; D000263:Adenylate Kinase / Q000032:analysis; D000641:Ammonia / Q000097:blood; D001706:Biopsy; D002110:Caffeine / Q000494:pharmacology; D003402:Creatine Kinase / Q000032:analysis; D005260:Female; D006580:Genetic Carrier Screening; D006221:Halothane / Q000494:pharmacology; D006720:Homozygote; D006801:Humans; D007527:Isoenzymes / Q000032:analysis / Q000172:deficiency*; D007773:Lactates / Q000097:blood; D019344:Lactic Acid; D008297:Male; D009119:Muscle Contraction / Q000187:drug effects; D009120:Muscle Cramp / Q000201:enzymology; D009132:Muscles / Q000201:enzymology*; D009709:Nucleotide Deaminases / Q000172:deficiency*; D005082:Physical Exertion
D007527:Isoenzymes; D007773:Lactates; D019344:Lactic Acid; D002110:Caffeine; D000641:Ammonia; D003402:Creatine Kinase; D000263:Adenylate Kinase; D009709:Nucleotide Deaminases; D000659:AMP Deaminase; D006221:Halothane